• Explore /
  • Poster
  • / LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).

LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).

Abstract Poster

Authors

Carey Anders

Carey K. Anders

University of North Carolina, Chapel Hill, NC

Carey K. Anders , Allison Mary Deal , Amanda Elyse Day Van Swearingen , Marni Siegel , David N. Hayes , Heejoon Jo , Paul Little , Elizabeth Claire Dees , Hyman B. Muss , Trevor Augustus Jolly , Timothy Zagar , J Keith Smith , Julie Gottlieb Fisher , Nikita C. Shah , Lisle Nabell , Rita Nanda , Patrick Michael Dillon , Shannon Puhalla , Vandana Gupta Abramson , Lisa A. Carey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT01305941

Citation

J Clin Oncol 35, 2017 (suppl; abstr 1011)

DOI

10.1200/JCO.2017.35.15_suppl.1011

Abstract #

1011

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Carey K. Anders

First Author: Ning Liao

First Author: Anna-Maria Lazaratos

First Author: Ian E. Krop